Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit-Reference-Cited by-同舟云学术

Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit

Published:2021-11 Issue: Volume: Page:
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Patel Anisha B.¹²^ORCID,Farooq Sahira²,Welborn Macartney³,Amaria Rodabe N.⁴,Chon Susan Y.¹,Diab Adi⁴,Glitza Oliva Isabella C.⁴,Huen Auris O.¹,Li Shirley Q.⁵,Nelson Kelly C.¹²,Pacha Omar¹,Patel Sapna P.⁴^ORCID,Rapini Ronald P.¹²,Tawbi Hussein A.⁴^ORCID,Wong Michael K.⁴,McQuade Jennifer⁴,Davies Michael A.⁴,Haydu Lauren E.⁶

Affiliation:

1. Department of Dermatology The University of Texas MD Anderson Cancer Center Houston Texas

2. McGovern Medical School The University of Texas Health Science Center Houston Texas

3. Department of Dermatology University of Florida Gainesville Florida

4. Department of Melanoma Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas

5. Baylor College of Medicine Houston Texas

6. Department of Surgical Oncology The University of Texas MD Anderson Cancer Center Houston Texas

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34004

Reference17 articles.

1. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

2. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

3. Pembrolizumab versus Ipilimumab in Advanced Melanoma

4. Treatment Outcomes of Immune-Related Cutaneous Adverse Events

5. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kutane Nebenwirkungen unter Immun-Checkpoint-Inhibitor-Therapie;Aktuelle Dermatologie;2023-11

2. Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features;Human Pathology;2023-10

3. Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review;International Journal of Molecular Sciences;2023-08-03

4. Updates in toxicities associated with immune checkpoint inhibitors;Expert Review of Clinical Immunology;2023-06-05

5. Mucocutaneous adverse events to immune checkpoint inhibitors;Frontiers in Allergy;2023-03-02